# Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

> **NCT00089089** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 42 (actual)

## Conditions studied

- Hematopoietic/Lymphoid Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** decitabine
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00089089
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-09
- **Primary completion:** 2008-03
- **Final completion:** —
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2013-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089089, "Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00089089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*